

## **REMARKS**

The specification has been amended in order to include the ATCC deposit information for the molecules of the invention and in order to remove all hyperlinks. Claims 1-40 were pending in the present application. Claims 1-40 have been canceled, without prejudice, and new claims 41-49 have been added. Accordingly, claims 41-49 will be pending upon entry of the instant amendment. Support for new claims 41-49 can be found throughout the specification and claims as originally filed. Specifically, support may be found at page 9, lines 17-35, at page 10, lines 16-22, at pages 11 and 12, beginning on line 26 of page 11, at page 47, lines 14-29, from line 11 of page 50 to line 4 of page 58, at page 86, lines 20-24 and at page 89, lines 6 to 11. No new matter has been added, and Applicants submit that all of the claims are now in condition for allowance.

August 4, 2003

Respectfully submitted,

MILLENVIUM PHARMACEUTICALS, INC.

By

Jean M. Silveri

Registration No. 39,030

75 Sidney Street

Cambridge, MA 02139 Telephone - 617-679-7336

Facsimile - 617-551-8820